TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04291001

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENG implant
Description: This is an FDA-approved contraceptive device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENG implant
Description: This is an FDA-approved contraceptive device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ulipristal acetate
Description: This is an FDA-approved oral emergency contraceptive
Study: NCT00251160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrothermal arthroscopic capsulorrhaphy (ETAC)
Description: The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open inferior capsular shift (ICS)
Description: MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
Study: NCT04676971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13
Description: Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline solution)
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Study: NCT00924170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-2
Description: Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days 1-3:~Patients 1-7, 10-14, and \>18:25mg/m\^2/day Patients 8 - 9:30 mg/m\^2/day Patients 15- 17:20 mg/m\^2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-3:~Patients 1-7, 10 -14, and \>18:250 mg/m\^2/day Patients 8 - 9:300 mg/m\^2/day Patients 15-17:200 mg/m\^2/day
Study: NCT01190423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Therapy for young adults
Description: Individual and Group Therapy Sessions
Study: NCT05121571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: sorafenib 400mg bid
Study: NCT03642093

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Walking and Inspiratory Muscle Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention
Description: Walking and Inspiratory Muscle Training
Study: NCT02598570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvelisib
Description: Duvelisib will be administered orally as a fixed dose in 28-day cycles.
Study: NCT02550977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
Study: NCT03585127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar Therapy
Description: Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
Study: NCT02486627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plazomicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meropenem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin (oral)
Study: NCT02962375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: 100% orange juice with orange pomace fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 100% orange juice
Study: NCT00625703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid.
Study: NCT00396448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment B
Description: Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment A
Description: Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
Study: NCT04489901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: To apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
Study: NCT01213667

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: upload (three monthly injections), re-treatment as needed
Study: NCT03487978

Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional MRI
Description: 1. To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~2. Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~3. On the third day after MRI, examine whether the subject has headache or not.

Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional MRI
Description: 1. To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~2. Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~3. On the third day after MRI, examine whether the subject has headache or not.
Study: NCT01654913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoglobin measurement
Description: Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~* at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~* with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~* with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin).
Study: NCT03603171

Intervention type: DIAGNOSTIC_TEST
Intervention: DM1-ActivC
Description: A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)

Intervention type: DIAGNOSTIC_TEST
Intervention: DM1-ActivC
Description: A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)

Intervention type: DIAGNOSTIC_TEST
Intervention: R-PAct
Description: A Rasch-built Pompe-specific activity scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: R-PAct
Description: A Rasch-built Pompe-specific activity scale.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck depression inventory
Description: A self-reported depression inventory administered verbally or self administered.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck depression inventory
Description: A self-reported depression inventory administered verbally or self administered.

Intervention type: DIAGNOSTIC_TEST
Intervention: McGill pain questionnaire
Description: The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.

Intervention type: DIAGNOSTIC_TEST
Intervention: McGill pain questionnaire
Description: The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Pain Inventory Short-Form
Description: A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning

Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Pain Inventory Short-Form
Description: A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning

Intervention type: DIAGNOSTIC_TEST
Intervention: Fatigue and Daytime Sleepiness Scale
Description: A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fatigue and Daytime Sleepiness Scale
Description: A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.

Intervention type: DIAGNOSTIC_TEST
Intervention: Myotonia Behaviour scale
Description: It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life

Intervention type: DIAGNOSTIC_TEST
Intervention: Myotonia Behaviour scale
Description: It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
Study: NCT02112058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Family-Strengthening Program for Low-Income Families
Description: The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.~Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.~The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program.
Study: NCT01805336

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of attentional functions by traditional tests
Description: For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
Study: NCT03603171

Intervention type: DIAGNOSTIC_TEST
Intervention: Scale for Assessment and Rating of Ataxia
Description: SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Berg balance scale
Description: It is a 14 item objective measure designed to assess static balance and fall risk in adult populations

Intervention type: DIAGNOSTIC_TEST
Intervention: Berg balance scale
Description: It is a 14 item objective measure designed to assess static balance and fall risk in adult populations

Intervention type: DIAGNOSTIC_TEST
Intervention: Quick motor function test
Description: Assessment of proximal motor function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quick motor function test
Description: Assessment of proximal motor function.

Intervention type: DIAGNOSTIC_TEST
Intervention: GSGC
Description: GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
Study: NCT03603171

Intervention type: DIAGNOSTIC_TEST
Intervention: GSGC
Description: GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.

Intervention type: DIAGNOSTIC_TEST
Intervention: 30 seconds sit to stand test
Description: It is a measurement that assesses functional lower extremity strenght in older adults.
Study: NCT04387838

Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-SARS-CoV2 Serology
Description: A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
Study: NCT03603171

Intervention type: DIAGNOSTIC_TEST
Intervention: 30 seconds sit to stand test
Description: It is a measurement that assesses functional lower extremity strenght in older adults.

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional Index-2
Description: Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional Index-2
Description: Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Six minute walking test
Description: It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Six minute walking test
Description: It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
Study: NCT01805336

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of attentional functions by virtual reality tests
Description: For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of attentional functions by virtual reality tests
Description: For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of executive functions by traditional tests
Description: For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
Study: NCT03603171

Intervention type: DIAGNOSTIC_TEST
Intervention: Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)
Description: A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)
Description: A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
Study: NCT03906916

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 1,3-β-D-glucan quantification
Description: Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
Study: NCT00933413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 21 consecutive days
Study: NCT03608761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: rebamipide 2%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous serum
Description: AS for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous serum and rebamipide 2%
Description: rebamipide and autologous serum for 3 months
Study: NCT02502006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03430453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of the minimal intensity of stimulation during ultrasound guided peripheral nerve blockade
Description: A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed. The Minimal Intensity of Stimulation is recorded before injection of local anesthetic
Study: NCT02522871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS™ Liver System

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study: NCT04045509

Intervention type: DEVICE
Group type: OTHER
Intervention: Liquid Jet Esthesiometer Prototype
Description: Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
Study: NCT04387838

Intervention type: OTHER
Intervention: Questionnaire
Description: Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age~* Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital~* Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures
Study: NCT01721395

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave Syrup
Study: NCT01805336

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of executive functions by traditional tests
Description: For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of executive functions by virtual reality test
Description: For assessment of executive functions, virtual reality test include : VAP-S.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of executive functions by virtual reality test
Description: For assessment of executive functions, virtual reality test include : VAP-S.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of cognitive complaint, fatigue, anxiety and depression
Description: The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of cognitive complaint, fatigue, anxiety and depression
Description: The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.